News

UK-based AstraZeneca has reported results from its longest, randomised, head-to-head DURATION-3 trial of exenatide once-weekly, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes in adult patients uncontrolled on oral antidiabetic drugs. ...

US-based Boston Therapeutics (BTI) has started a Phase IIb clinical trial SD-002 to evaluate the efficacy and safety of Sugardown in patients with type 2 diabetes taking metformin. Accumed Research Associates is conducting the 24-patient five-week,...

Veterans trying to schedule medical appointments in the Veterans Affairs Department’s Phoenix Health Care System entered a Kafkaesque world where they had to call a “helpline” to provide demographic information to an official who would type the data into...

GAINESVILLE, Fla. — At the conclusion of the first year of UF Health’s Personalized Medicine Program, the results are in: The program has successfully implemented a process for genetic testing that helps cardiologists identify which patients may benefit from...

GlaxoSmithKline (GSK) and Medicines for Malaria Venture (MMV) have initiated a Phase III global programme to assess the efficacy and safety of tafenoquine, an investigational medicine, being developed for the treatment and relapse prevention (radical cure) of Plasmodium vivax...

US-based Ohr Pharmaceutical has completed patient enrolment in its OHR-002 Phase II clinical trial evaluating Squalamine Eye Drops for treatment of the wet form of age related macular degeneration (wet-AMD). A total of 142 treatment naive...

Teva Pharmaceutical has obtained marketing authorisation approval from European Commission for its DuoResp Spiromax for treatment of patients with asthma and chronic obstructive pulmonary disease (COPD) when a combination inhaled corticosteroid and long-acting beta(2) adrenoceptor agonist is appropriate. ...